AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study

被引：0
|
作者：
Cortes, Jorge [1 ]
Foran, James [8 ]
Ghirdaladze, Darejan [7 ]
DeVetten, Marcel P. [6 ]
Zodelava, Mamia [5 ]
Holman, Peter [4 ]
Levis, Mark J. [3 ]
Kantarjian, Hagop M. [1 ]
Borthakur, Gautam [1 ]
James, Joyce [2 ]
Zarringkar, Patrick P. [2 ]
Gunawardane, Ruwanthi N. [2 ]
Armstrong, Robert C. [2 ]
Padre, Norman M. [2 ]
Wierenga, Wendell [2 ]
Corringham, Robert [2 ]
Trikha, Mohit [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Ambit Biosci, San Diego, CA USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] Hema Clin, Tbilisi, Georgia
[6] Univ Nebraska, Med Ctr, Omaha, NE USA
[7] Medulla Clin, Tbilisi, Georgia
[8] Univ Alabama Birmingham, Birmingham, AL USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：264 / 264
页数：1
相关论文
共 50 条
  • [21] First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2
    Catlett, Ian M.
    Aras, Urvi
    Hansen, Lars
    Liu, Yali
    Bei, Di
    Girgis, Ihab G.
    Murthy, Bindu
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (01): : 151 - 164
  • [22] A FIRST-IN-HUMAN, STUDY OF BMS-986165, A SELECTIVE, POTENT, ALLOSTERIC SMALL MOLECULE INHIBITOR OF TYROSINE KINASE 2
    Catlett, I.
    Aras, U.
    Liu, Y.
    Bei, D.
    Girgis, I.
    Murthy, B.
    Honczarenko, M.
    Rose, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 859 - 859
  • [23] Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)
    Levis, Mark J.
    Perl, Alexander E.
    Altman, Jessica K.
    Cortes, Jorge E.
    Ritchie, Ellen K.
    Larson, Richard A.
    Smith, Catherine Choy
    Wang, Eunice S.
    Strickland, Stephen Anthony
    Baer, Maria R.
    Litzow, Mark Robert
    Claxton, David
    Schiller, Gary J.
    Ustun, Celalettin
    Liu, Charles
    Gill, Stan
    Sargent, Briana
    Bahceci, Erkut
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
    Schwartz, Gary K.
    Adkins, Douglas
    Heist, Rebecca Suk
    Abbott, Maura
    Barber, Stephanie L.
    Chao, Richard C.
    Neuteboom, Saskia T. C.
    Chen, Isan
    Christensen, James
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
    Perl, A.
    Altman, J.
    Cortes, J.
    Levis, M.
    Smith, C.
    Litzow, M.
    Baer, M. R.
    Claxton, D.
    Erba, H.
    Gill, S.
    Goldberg, S.
    Jurcic, J.
    Larson, R. A.
    Liu, C.
    Ritchie, E.
    Sargent, B.
    Schiller, G.
    Spira, A.
    Strickland, S.
    Tibes, R.
    Ustun, C.
    Wang, E. S.
    Stuart, R.
    Bahceci, E.
    HAEMATOLOGICA, 2015, 100 : 317 - 318
  • [26] HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study
    Daver, Naval
    Lee, Kyoo Hyung
    Jung, Chul Won
    Soo, Yoon Sung
    Arellano, Martha L.
    Jonas, Brian A.
    Yoon, Jiyeon
    Jung, Sooa
    Noh, Young Su
    Bae, Inhwan
    Kim, Song
    BLOOD, 2020, 136
  • [27] Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study
    Smith, Catherine C.
    Levis, Mark. J.
    Litzow, Mark R.
    Perl, Alexander E.
    Altman, Jessica K.
    Gill, Stanley C.
    Kadokura, Takeshi
    Yuen, Geoffrey J.
    Fisniku, Ogert
    Liu, Charles
    Nagase, Itsuro
    Sargent, Briana
    Welter, Noreen
    Bahceci, Erkut
    BLOOD, 2015, 126 (23)
  • [28] Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.
    Levis, Mark J.
    Smith, Catherine Choy
    Perl, Alexander E.
    Schiller, Gary J.
    Fathi, Amir Tahmasb
    Roboz, Gail J.
    Wang, Eunice S.
    Altman, Jessica K.
    Ando, Makoto
    Suzuki, Takeaki
    Subach, Ruth Ann
    Maier, Gary
    Madden, Timothy
    Johansen, Mary
    Cheung, Kin
    Kurman, Michael R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase
    Leu, Jocelyn H.
    Miao, Xin
    Shalayda, Kevin
    Coe, Kevin J.
    Kahnt, Ariane
    Wu, Bonnie
    Schnarr, Megan
    Franks, Carol
    Devlin, James
    Yang, Tong-Yuan
    Palmer, James A.
    Zhang, Mai
    Zhou, Honghui
    Van Damme, Wim
    Smets, Sophie
    Aguilar, Zuleima
    Chaplan, Sandra R.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (06): : 611 - 624
  • [30] A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
    Bauer, Todd Michael
    Adkins, Douglas
    Schwartz, Gary K.
    Werner, Theresa Louise
    Alva, Ajjai Shivaram
    Hong, David S.
    Carvajal, Richard D.
    Saleh, Mansoor N.
    Bazhenova, Lyudmila
    Goel, Sanjay
    Eaton, Keith D.
    Siegel, Robert D.
    Wang, Ding
    Lauer, Richard C.
    Neuteboom, Saskia T. C.
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Chao, Richard C.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345